Pipeline
We are committed to developing best-in-class therapeutics for patients with high unmet need across a wide range of diseases.
We aim to discover and develop innovative therapeutics across a broad range of diseases in order to realize the transformative potential of previously undruggable targets, including SLCs. We are advancing an internal pipeline of programs in immune-mediated diseases, oncology and metabolite-dependent diseases. Collaborations with biopharma partners are a critical part of our strategy, giving us additional opportunities to leverage the RAPID platform and address patient needs, including in therapeutic areas outside of our current internal focus.
